A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs BI 836858 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 24 Sep 2019 Status changed from suspended to active, no longer recruiting.
- 20 Aug 2019 Planned primary completion date changed from 17 Dec 2021 to 20 Jan 2020.
- 13 Jun 2019 Status changed from recruiting to suspended.